Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Tecfidera

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tecfidera was produced by Biogen Idec.

The good, the bad and the ugly

The good, the bad and the ugly

Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen cuts $217m deal for Karyopharm neurology drug Biogen reported 2017 revenues of $12.3bn, up 15% on the prior year, thanks to gains for its multiple sclerosis drugs, particularly Tecfidera (dimethyl fumarate) and rising royalties from Ocrevus (ocrelizumab) -

Sanofi licences Principia MS drug in $805m deal

Sanofi licences Principia MS drug in $805m deal With a 27% growth it is still one of Sanofi’s most important products, but is still lagging behind Biogen’s market-leading Tecfidera (dimethyl fumarate) which brought in almost

Merck gets CHMP backing for long-delayed oral MS drug

Merck gets CHMP backing for long-delayed oral MS drug competitive landscape" - with oral therapies such as Novartis' Gilenya (fingolimod) and Biogen's Tecfidera (dimethyl glutamate) reaching or near the market. ... Mavenclad will launch into a market where Tecfidera is currently dominating with sales of

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics